Novartis Ag (NVS) 80.67 $NVS
Incyte Gains on Jakafi's Breakthrough Status for Acute GVHD
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 5:07PM CDT
Incyte (INCY) announced that the FDA has granted Breakthrough Therapy status to Jakafi for the treatment of patients with acute graft-versus-host disease.
INCY: 81.66 (+3.16), LLY: 73.94 (+0.87), BMY: 72.64 (+0.33), NVS: 80.67 (+0.96)
Genmab/Novartis' Arzerra Gets Unfavorable CHMP Opinion
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 11:17AM CDT
Genmab (GNMSF) announced that CHMP issued a negative opinion for Arzerra as a maintenance therapy for relapsed chronic lymphatic leukemia.
JNJ: 117.38 (+0.92), ANIP: 56.27 (+3.48), NVS: 80.67 (+0.96)
Pigmented Villonodular Synovitis Pipeline Report 2016 - Therapeutic Review of F. Hoffmann-La Roche, Five Prime Therapeutics, Novartis & Plexxikon - Research and Markets
BusinessWire - Fri Jun 24, 4:54AM CDT
Research and Markets has announced the addition of the "Pigmented Villonodular Synovitis - Pipeline Review, H1 2016" report to their offering.
NVS: 80.67 (+0.96)
Genmab Provides Update on Marketing Authorization Application for Arzerra(r) (ofatumumab) as Maintenance Therapy for Patients with Relapsed CLL
GlobeNewswire - Thu Jun 23, 9:33AM CDT
-- Committee for Medicinal Products for Human Use (CHMP) issues negative opinion for Arzerra for maintenance treatment of patients with relapsed CLL
GEN: 1.72 (+0.05), NVS: 80.67 (+0.96)
Annexon Biosciences Closes $44 Million Series B Financing
BusinessWire - Thu Jun 23, 7:30AM CDT
Annexon Biosciences, a biopharmaceutical company pioneering the development of classical complement pathway inhibitors to treat neurodegenerative disorders, today announced that it has closed a $44 million Series B financing. The Series B financing was led by new investor New Enterprise Associates (NEA), with participation by Correlation Ventures and existing Annexon investors, including Novartis Venture Fund, Clarus, and Satter Investment Management, LLC. In conjunction with the financing, Frank Torti, M.D., a Partner at NEA, has joined the company's Board of Directors.
NVS: 80.67 (+0.96)
IFM Therapeutics Raises $27 Million Series A Financing Led by Atlas Venture and Abingworth
BusinessWire - Wed Jun 22, 6:00AM CDT
IFM Therapeutics, a biopharmaceutical company developing a portfolio of first-in-class small molecules targeting the innate immune system, today announced the closing of a $27 million Series A financing led by Atlas Venture and Abingworth, with participation from Novartis. In conjunction with the funding Jean-Francois Formela and Vincent Miles, Partners at Atlas and Abingworth respectively, have joined IFM's CEO, Gary D. Glick, on the board of directors, with Dr. Formela serving as chair of the board.
NVS: 80.67 (+0.96)
Possible Bearish Inside Day Candle Pattern Detected for Novartis (NYSE:NVS) - June 21, 2016
Comtex SmarTrend(R) - Tue Jun 21, 10:05AM CDT
SmarTrend's candlestick scanner has spotted a possible bearish inside day candle pattern in Novartis (NYSE:NVS) based on the price action in the company's shares. Today's price range of $78.97 and $79.40 is within yesterday's high and low of the day. This trading action often signifies indecision by bulls and bears to drive prices higher or lower and often implies a possible change in trend. Owners of Novartis may want to consider a possible hedge in the event a pullback occurs. Look for confirmation in the next few trading days.Novartis AG manufactures pharmaceutical and consumer healthcare products. The Company produces pharmaceuticals for cardiovascular, respiratory and infectious diseases, oncology, neuroscience, transplantation, ophthalmics, dermatology, gastrointestinal and urinary conditions, and arthritis, vaccines and diagnostics, generics, and over-the-counter, vision, and animal health products.
NVS: 80.67 (+0.96)
FLAME study evaluating efficacy of Ultibro® Breezhaler® to reduce chronic COPD exacerbations published in NEJM
CNW Group - Tue Jun 21, 7:01AM CDT
Results published in the New England Journal of Medicine are anticipated to have important implications for the care of people living with COPD.
NVS: 80.67 (+0.96)
International Data Corporation (IDC) Lauds Innovations in Supercomputing with Innovation Excellence Awards
BusinessWire - Tue Jun 21, 1:30AM CDT
International Data Corporation (IDC) today announced the tenth round of recipients of the HPC Innovation Excellence Award at ISC16, a major international supercomputing conference, in Frankfurt, Germany. This year's winners include The Centre for Computational Medicine, University of Toronto; Walt Disney Animation Studios; DreamWorks Animation; Fortissimo/Ergolines GPUdb; United States Postal Service; Novartis/Amazon Web Services (AWS)/Cycle Computing; and the University of Rochester Medical Center. They join the elite ranks of over 60 previous recipients from around the world, the first having been announced in 2011.
NVS: 80.67 (+0.96)
CNS Drug News Report 2016 - Digital Healthcare Partnerships Offer Expedited Development Potential - Research and Markets
BusinessWire - Mon Jun 20, 10:29AM CDT
Research and Markets has announced the addition of the "CNS Drug News Issue 372" report to their offering.
NVS: 80.67 (+0.96)
Cytochrome P450 11B2 Mitochondrial Pipeline Review, H1 2016 Featuring Angion Biomedica Corp, Merck & Co., & Novartis AG - Research and Markets
BusinessWire - Fri Jun 17, 1:01PM CDT
Research and Markets has announced the addition of the "Cytochrome P450 11B2 Mitochondrial - Pipeline Review, H1 2016" report to their offering.
MRK: 57.68 (+0.64), NVS: 80.67 (+0.96)
Blade Therapeutics Raises $45 Million Series B Financing with Unparalleled Syndicate of VCs and Strategic Pharma Investors
BusinessWire - Thu Jun 16, 8:00AM CDT
Blade Therapeutics, a private biopharmaceutical company revolutionizing the treatment of fibrotic disease, today announced the closing of a Series B financing led by Deerfield Management, that will bring $45 million into the company when all milestones are completed. Proceeds from the financing will be used to advance the selection and development of lead molecules designed to modify the pathobiology of fibrotic diseases. The round included new investors Deerfield Management and Pfizer Venture Investments with new equity investments also made by Novartis Institutes for Biomedical Research and Bristol-Myers Squibb. Blade's existing investors, MPM Capital and Osage University Partners, also participated to their full pro rata in the capital raise. Joining the Board of Directors will be William Slattery and Cameron Wheeler, Ph.D. from Deerfield Management and Elaine Jones, Ph.D. from Pfizer Venture Investments. The seven-member Board also includes MPM's James Scopa, J.D. and M.B.A, Luke Evnin, Ph.D., Peter Van Vlasselaer, Ph.D. ARMO Biosciences, and Chief Executive Officer Wendye Robbins, M.D.
BMY: 72.64 (+0.33), NVS: 80.67 (+0.96)
Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment
Globe Newswire - Wed Jun 15, 12:15AM CDT
Novartis International AG / Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 80.67 (+0.96)
ARIAD (ARIA) Presents Long-Term Phase II Data on Iclusig
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 5:25PM CDT
ARIAD (ARIA) presented long-term follow-up phase II PACE study data on its leukemia drug, Iclusig.
ARIA: 7.54 (+0.27), BMY: 72.64 (+0.33), ORPN: 1.74 (-0.01), NVS: 80.67 (+0.96)
Amgen's Biosimilar of AbbVie's Humira to Face FDA Panel
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 9:59AM CDT
Amgen's (AMGN) biosimilar version of AbbVie's best-selling drug, Humira, will face the FDA's Arthritis Advisory Committee.
AMGN: 152.27 (+2.46), ABBV: 61.31 (+0.92), BMY: 72.64 (+0.33), NVS: 80.67 (+0.96)
Watch for Novartis to Potentially Rebound After Falling 1.81% Yesterday
Comtex SmarTrend(R) - Mon Jun 13, 12:55PM CDT
Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $77.37 to a high of $78.26. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $78.62 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVS: 80.67 (+0.96)
After Yesterday's Decline of 1.81%, Novartis Offers Investors Better Value
Comtex SmarTrend(R) - Mon Jun 13, 12:53PM CDT
Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $77.37 to a high of $78.26. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $78.62 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVS: 80.67 (+0.96)
Global Cytomegalovirus (HHV-5) Infections Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Novartis, Chimerix, Gilead Sciences - Research and Markets
BusinessWire - Fri Jun 10, 10:31AM CDT
Research and Markets has announced the addition of the "Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
NVS: 80.67 (+0.96)
Novartis Reports Positive Data on Biosimilar Candidates
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 10:19AM CDT
Novartis AG (NVS) announced results from two key studies comparing its proposed biosimilar versions of Amgen's (AMGN) blockbuster drug, Enbrel (etanercept), and Roche's (RHHBY) Mabthera (rituximab) to the reference drugs.
NVS: 80.67 (+0.96)
Novartis highlights long-term safety data of Revolade(R) in adults with chronic immune thrombocytopenia, a rare blood disorder
Globe Newswire - Fri Jun 10, 1:31AM CDT
Novartis International AG / Novartis highlights long-term safety data of Revolade(R) in adults with chronic immune thrombocytopenia, a rare blood disorder . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 80.67 (+0.96)
Incyte Gains on Jakafi's Breakthrough Status for Acute GVHD
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 5:07PM CDT
Incyte (INCY) announced that the FDA has granted Breakthrough Therapy status to Jakafi for the treatment of patients with acute graft-versus-host disease.
INCY: 81.66 (+3.16), LLY: 73.94 (+0.87), BMY: 72.64 (+0.33), NVS: 80.67 (+0.96)
Genmab/Novartis' Arzerra Gets Unfavorable CHMP Opinion
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 11:17AM CDT
Genmab (GNMSF) announced that CHMP issued a negative opinion for Arzerra as a maintenance therapy for relapsed chronic lymphatic leukemia.
JNJ: 117.38 (+0.92), ANIP: 56.27 (+3.48), NVS: 80.67 (+0.96)
Pigmented Villonodular Synovitis Pipeline Report 2016 - Therapeutic Review of F. Hoffmann-La Roche, Five Prime Therapeutics, Novartis & Plexxikon - Research and Markets
BusinessWire - Fri Jun 24, 4:54AM CDT
Research and Markets has announced the addition of the "Pigmented Villonodular Synovitis - Pipeline Review, H1 2016" report to their offering.
NVS: 80.67 (+0.96)
Genmab Provides Update on Marketing Authorization Application for Arzerra(r) (ofatumumab) as Maintenance Therapy for Patients with Relapsed CLL
GlobeNewswire - Thu Jun 23, 9:33AM CDT
-- Committee for Medicinal Products for Human Use (CHMP) issues negative opinion for Arzerra for maintenance treatment of patients with relapsed CLL
GEN: 1.72 (+0.05), NVS: 80.67 (+0.96)
Annexon Biosciences Closes $44 Million Series B Financing
BusinessWire - Thu Jun 23, 7:30AM CDT
Annexon Biosciences, a biopharmaceutical company pioneering the development of classical complement pathway inhibitors to treat neurodegenerative disorders, today announced that it has closed a $44 million Series B financing. The Series B financing was led by new investor New Enterprise Associates (NEA), with participation by Correlation Ventures and existing Annexon investors, including Novartis Venture Fund, Clarus, and Satter Investment Management, LLC. In conjunction with the financing, Frank Torti, M.D., a Partner at NEA, has joined the company's Board of Directors.
NVS: 80.67 (+0.96)
IFM Therapeutics Raises $27 Million Series A Financing Led by Atlas Venture and Abingworth
BusinessWire - Wed Jun 22, 6:00AM CDT
IFM Therapeutics, a biopharmaceutical company developing a portfolio of first-in-class small molecules targeting the innate immune system, today announced the closing of a $27 million Series A financing led by Atlas Venture and Abingworth, with participation from Novartis. In conjunction with the funding Jean-Francois Formela and Vincent Miles, Partners at Atlas and Abingworth respectively, have joined IFM's CEO, Gary D. Glick, on the board of directors, with Dr. Formela serving as chair of the board.
NVS: 80.67 (+0.96)
Possible Bearish Inside Day Candle Pattern Detected for Novartis (NYSE:NVS) - June 21, 2016
Comtex SmarTrend(R) - Tue Jun 21, 10:05AM CDT
SmarTrend's candlestick scanner has spotted a possible bearish inside day candle pattern in Novartis (NYSE:NVS) based on the price action in the company's shares. Today's price range of $78.97 and $79.40 is within yesterday's high and low of the day. This trading action often signifies indecision by bulls and bears to drive prices higher or lower and often implies a possible change in trend. Owners of Novartis may want to consider a possible hedge in the event a pullback occurs. Look for confirmation in the next few trading days.Novartis AG manufactures pharmaceutical and consumer healthcare products. The Company produces pharmaceuticals for cardiovascular, respiratory and infectious diseases, oncology, neuroscience, transplantation, ophthalmics, dermatology, gastrointestinal and urinary conditions, and arthritis, vaccines and diagnostics, generics, and over-the-counter, vision, and animal health products.
NVS: 80.67 (+0.96)
FLAME study evaluating efficacy of Ultibro® Breezhaler® to reduce chronic COPD exacerbations published in NEJM
CNW Group - Tue Jun 21, 7:01AM CDT
Results published in the New England Journal of Medicine are anticipated to have important implications for the care of people living with COPD.
NVS: 80.67 (+0.96)
International Data Corporation (IDC) Lauds Innovations in Supercomputing with Innovation Excellence Awards
BusinessWire - Tue Jun 21, 1:30AM CDT
International Data Corporation (IDC) today announced the tenth round of recipients of the HPC Innovation Excellence Award at ISC16, a major international supercomputing conference, in Frankfurt, Germany. This year's winners include The Centre for Computational Medicine, University of Toronto; Walt Disney Animation Studios; DreamWorks Animation; Fortissimo/Ergolines GPUdb; United States Postal Service; Novartis/Amazon Web Services (AWS)/Cycle Computing; and the University of Rochester Medical Center. They join the elite ranks of over 60 previous recipients from around the world, the first having been announced in 2011.
NVS: 80.67 (+0.96)
CNS Drug News Report 2016 - Digital Healthcare Partnerships Offer Expedited Development Potential - Research and Markets
BusinessWire - Mon Jun 20, 10:29AM CDT
Research and Markets has announced the addition of the "CNS Drug News Issue 372" report to their offering.
NVS: 80.67 (+0.96)
Cytochrome P450 11B2 Mitochondrial Pipeline Review, H1 2016 Featuring Angion Biomedica Corp, Merck & Co., & Novartis AG - Research and Markets
BusinessWire - Fri Jun 17, 1:01PM CDT
Research and Markets has announced the addition of the "Cytochrome P450 11B2 Mitochondrial - Pipeline Review, H1 2016" report to their offering.
MRK: 57.68 (+0.64), NVS: 80.67 (+0.96)
Blade Therapeutics Raises $45 Million Series B Financing with Unparalleled Syndicate of VCs and Strategic Pharma Investors
BusinessWire - Thu Jun 16, 8:00AM CDT
Blade Therapeutics, a private biopharmaceutical company revolutionizing the treatment of fibrotic disease, today announced the closing of a Series B financing led by Deerfield Management, that will bring $45 million into the company when all milestones are completed. Proceeds from the financing will be used to advance the selection and development of lead molecules designed to modify the pathobiology of fibrotic diseases. The round included new investors Deerfield Management and Pfizer Venture Investments with new equity investments also made by Novartis Institutes for Biomedical Research and Bristol-Myers Squibb. Blade's existing investors, MPM Capital and Osage University Partners, also participated to their full pro rata in the capital raise. Joining the Board of Directors will be William Slattery and Cameron Wheeler, Ph.D. from Deerfield Management and Elaine Jones, Ph.D. from Pfizer Venture Investments. The seven-member Board also includes MPM's James Scopa, J.D. and M.B.A, Luke Evnin, Ph.D., Peter Van Vlasselaer, Ph.D. ARMO Biosciences, and Chief Executive Officer Wendye Robbins, M.D.
BMY: 72.64 (+0.33), NVS: 80.67 (+0.96)
Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment
Globe Newswire - Wed Jun 15, 12:15AM CDT
Novartis International AG / Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 80.67 (+0.96)
ARIAD (ARIA) Presents Long-Term Phase II Data on Iclusig
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 5:25PM CDT
ARIAD (ARIA) presented long-term follow-up phase II PACE study data on its leukemia drug, Iclusig.
ARIA: 7.54 (+0.27), BMY: 72.64 (+0.33), ORPN: 1.74 (-0.01), NVS: 80.67 (+0.96)
Amgen's Biosimilar of AbbVie's Humira to Face FDA Panel
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 9:59AM CDT
Amgen's (AMGN) biosimilar version of AbbVie's best-selling drug, Humira, will face the FDA's Arthritis Advisory Committee.
AMGN: 152.27 (+2.46), ABBV: 61.31 (+0.92), BMY: 72.64 (+0.33), NVS: 80.67 (+0.96)
Watch for Novartis to Potentially Rebound After Falling 1.81% Yesterday
Comtex SmarTrend(R) - Mon Jun 13, 12:55PM CDT
Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $77.37 to a high of $78.26. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $78.62 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVS: 80.67 (+0.96)
After Yesterday's Decline of 1.81%, Novartis Offers Investors Better Value
Comtex SmarTrend(R) - Mon Jun 13, 12:53PM CDT
Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $77.37 to a high of $78.26. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $78.62 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVS: 80.67 (+0.96)
Global Cytomegalovirus (HHV-5) Infections Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Novartis, Chimerix, Gilead Sciences - Research and Markets
BusinessWire - Fri Jun 10, 10:31AM CDT
Research and Markets has announced the addition of the "Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
NVS: 80.67 (+0.96)
Novartis Reports Positive Data on Biosimilar Candidates
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 10:19AM CDT
Novartis AG (NVS) announced results from two key studies comparing its proposed biosimilar versions of Amgen's (AMGN) blockbuster drug, Enbrel (etanercept), and Roche's (RHHBY) Mabthera (rituximab) to the reference drugs.
NVS: 80.67 (+0.96)
Novartis highlights long-term safety data of Revolade(R) in adults with chronic immune thrombocytopenia, a rare blood disorder
Globe Newswire - Fri Jun 10, 1:31AM CDT
Novartis International AG / Novartis highlights long-term safety data of Revolade(R) in adults with chronic immune thrombocytopenia, a rare blood disorder . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 80.67 (+0.96)
